Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.43 |
| ▸ | TERT | O14746 | 4/20 | 0.42 |
| ▸ | CYCS | P99999 | 3/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358555 | 0.99 | TOP1 (0.42) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL14181439 | 0.96 | STAT3 (0.46) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL1315604 | 0.92 | TOP1 (0.37) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL31167372 | 0.92 | RIPK1 (0.43) | RIPK1MGAMGAASIMGAM2 | |
| SCHEMBL498511 | 0.92 | RIPK1 (0.43) | RIPK1MGAMGAASIMGAM2 | |
| SCHEMBL29556430 | 0.90 | TOP1 (0.50) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL31296593 | 0.90 | TOP1 (0.50) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL249199 | 0.90 | TOP1 (0.50) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL29648445 | 0.89 | TERT (0.51) | TOP1TERTCYCSENPP2STAT3 | |
| SCHEMBL30297908 | 0.89 | TERT (0.51) | TOP1TERTCYCSENPP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17576 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622964-B2 | Modular phage vector platform for sonodynamic therapy | Alma Mater Studiorum—Universita' di Bologna (IT) | 2026-05-12 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| WO-2026044015-A1 | SONODYNAMIC THERAPY INVOLVING THIAMINE OR A DERIVATIVE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4612132-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2025-09-10 | — | — | EP | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| CN-120166987-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20030157026-A1 | Photodynamic diagnosis and therapy for insulin-dependent diabetes mellitus | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-08-21 | — | — | US | claimed |
| WO-2003008430-A2 | PORPHYRIN DERIVATIVES FOR PHOTODYNAMIC THERAPY | INSTITUT CURIE (FR) | 2003-01-30 | — | — | WO | claimed |
| US-20020192162-A1 | Methods for using annexin for detecting cell death in vivo and treating associated conditions | THESUS IMAGING CORPORATION | 2002-12-19 | — | — | US | claimed |
| WO-2002080754-A2 | METHODS FOR USING ANNEXIN FOR DETECTING CELL DEATH IN VIVO AND TREATING ASSOCIATED CONDITIONS | THESEUS IMAGING CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| US-6391026-B1 | Methods and systems for treating breast tissue | PRO DUCT HEALTH, INC. | 2002-05-21 | — | — | US | claimed |
| WO-2000016708-A9 | METHODS AND SYSTEMS FOR TREATING BREAST TISSUE | WINDY HILL TECHNOLOGY INC (US) | 2000-08-17 | — | — | WO | claimed |
| WO-2000016708-A1 | METHODS AND SYSTEMS FOR TREATING BREAST TISSUE | WINDY HILL TECHNOLOGY, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | claimed |
| US-4992257-A | Dihydroporphyrins and method of treating tumors | EFAMOL HOLDINGS PLC (GB) | 1991-02-12 | — | — | US | claimed |